Vilazodone: A novel antidepressant

American Journal of Health-System Pharmacy

Volumn 69, Issue 18, 2012, Pages 1551-1557

  Choi, Elizabeth ^a   Zmarlicka, Monika ^c   Ehret, Megan J ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; VILAZODONE;

ABNORMAL DREAMING; ANXIETY; BACKACHE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR DEPRESSION; NAUSEA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 84865975411     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110374     Document Type: Review

References (33)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000:317-91.
2. Kesseler RC, Chiu WT, Demler O et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005; 62:617-709.
3. Department of Health and Human Services. Mental health: a report of the surgeon general-executive summary. www.surgeongeneral.gov/library/ mentalhealth/home.html (accessed 2011 Jun 10).
4. Rush AJ. STAR&z.ast;D: what have we learned? Am J Psychiatry. 2007; 164:201-4.
5. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR&z.ast;D: implications for clinical practice. Am J Psychiatry. 2006; 163:28- 40.
6. Bartholow M. Top 200 drugs of 2010. Pharmacy Times. 2011; 5:52-9.
7. Celeda P, Puig MV, Amargos-Bosch M et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004; 29:252-65. (Pubitemid 39185866)
8. Kalia R, Mittal MS, Preskorn SH. Vilazodone for major depressive disorder. Curr Psychiatry. 2011; 10:84-8.
9. Heinrich T, Bottcher H, Schiemann K et al. Dual 5-HT1A agonists and 5-HT reuptake inhibitors by combination of indole-butyl-amine and chromenonylpiperazine structural elements in a single molecular entity. Bioorg Med Chem. 2004; 12:4843-52. (Pubitemid 39164392)
10. Heinrich T, Bottcher H, Gericke R et al. Synthesis and structure-activity relationship in a class of indolebutylpiperazines as dual 5-HT1A receptor agonists and serotonin reuptake inhibitors. J Med Chem. 2004; 47:4684-92. (Pubitemid 39195559)
11. Viibryd (vilazodone hydrochloride) package insert. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2011 Apr.
12. Araneda R, Andrade R. 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 1991; 40:399-412.
13. Artigas F, Celeda P, Laruelle M et al. How does pindolol improve antidepressant action? Trends Pharmacol Sci. 2001; 22:224- 8.
14. Page ME, Cryan JF, Sullivan A et al. Behavioral and neurochemical effects of 5-(4-[4-(5-cyano-3-indolyl)-butyl)- butyl]-1-piperazinyl)-benzofuran-2- carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine1A receptor partial agonist. J Pharmacol Exp Ther. 2002; 302:1220-7. (Pubitemid 34920246)
15. Hughes ZA, Starr KR, Langmead CJ et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin re-uptake inhibitor, vilazodone. Eur J Pharmacol. 2005; 510:49-57. (Pubitemid 40312389)
16. Roberts C, Hagan JJ, Bartoszyk GD et al. Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus. Eur J Pharmacol. 2005; 517:59-63. (Pubitemid 40910253)
17. Howland RH. Vilazodone: another novel atypical antidepressant drug. J Psychosoc Nurs. 2011; 49:19-22.
18. Forest Pharmaceuticals. Viibryd (vilazodone hydrochloride) Tablets. www.frx.com/ pi/viibryd-pi.pdf (accessed 2012 Jul 6).
19. Alcorn H, Longstreth J, Swan SK et al. Vilazodone pharmacokinetics in subjects with mild to moderate renal impairment. Poster presented at American Psychiatric Association Annual Meeting, New Orleans, LA; 2010 May 25.
20. Rabiner EA, Gunn RN, Wilkins MR et al. Drug action at the 5-HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-11C ]WAY-100635. Nucl Med Biol. 2000; 27:509-13. (Pubitemid 30658155)
21. Rickels K, Athanasiou M, Robinson DS et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial . J Clin Psychiatry. 2009; 70:326-33.
22. Khan A, Cutler AJ, Kajdasz DK et al. A randomized, double-blind, placebocontrolled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011; 72:441-7.
23. Rickels K, Athanasiou M, Reed C. Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression. Pers Med . 2009; 6:217-24.
24. Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs. 2009; 18:1753-64.
25. Hamilton D. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967; 6:278-96.
26. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382-9. (Pubitemid 9136500)
27. Guy W, ed. Clinical global impressions. ECDEU assessment manual for psychopharmacology. Rockville, MD: Department of Health, Education, and Welfare; 1976. DHEW publication no. (ADM) 76-338.
28. Robinson DS, Kajdasz DK, Gallipoli S et al. A 1-year open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. Poster presented at American Psychiatric Association Annual Meeting, New Orleans, LA; 2010 May 25.
29. Garnock-Jones KP, McCormack PL. Escitalopram: a review of its use in the management of major depressive disorder in adults. CNS Drugs. 2010; 24:769- 96.
30. Dawson LA, Watson JM. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorder. CNS Neurosci Ther. 2009; 15:107-17.
31. Rickels K. Buspirone in clinical practice. J Clin Psychiatry. 1990; 51:51-4. (Pubitemid 20382333)
32. Appleberg BG, Syvalahti EK, Koskinen TE et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebocontrolled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001; 62:448-52.
33. Thomson Reuters Micromedex Clinical Evidence Solutions. New York: Thomson Reuters Healthcare; 2011.